Form 4: ACM Research chief gains 545,400 option vesting at $7.36
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ACM Research (ACMR) Form 4: CEO, President and Director David H. Wang reported vesting and acquisition of 545,400 stock options at an exercise price of $7.36 on October 27, 2025, from a 2020 performance grant. These options are now exercisable and expire on March 19, 2030.
The vesting occurred after the company’s market capitalization reached $2,553,383,586 under the grant’s formula; remaining tranches vest if market cap reaches $3,553,383,586. Indirect beneficial holdings disclosed include 620,001 shares (Wang‑Chen Family Living Trust), 180,000 (Family Irrevocable Trust for Wang Children), 100,002 (spouse), and 45,837 (daughter).
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Wang David H
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 545,400 | $0.00 | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 545,400 shares (Direct);
Class A Common Stock — 100,002 shares (Indirect, By Jing Chen, wife of David H. Wang)
Footnotes (1)
- On March 20, 2020, the reporting person was granted options to purchase an aggregate of 1,636,197 shares of the Issuer's Class A common stock, based on the satisfaction of certain performance criteria. In general, one-third of the shares subject to the options vest and become exercisable upon an increase in the Issuer's market capitalization (calculated as described in footnote 2) of $1 billion, $2 billion and $3 billion, respectively, from the market capitalization of $553,383,586 on the date of grant. 545,400 shares vested and became exercisable on October 27, 2025, which was the first trading day as of which the Issuer's market capitalization equaled or exceeded $2,553,383,586. The remaining shares will vest and become exercise upon the first trading days, if any, on which the Issuer's market capitalization equals or exceeds $3,553,383,586. For purposes of the options, the market capitalization as of a specified trading day is calculated by multiplying (a) the average of the daily volume-weighted average price per share of the Issuer's Class A common stock for each of the trading days occurring during the thirty calendar day period ending on that specified trading day by (b) the total number of issued and outstanding shares of the Issuer's Class A and Class B common stock as of 11:59 p.m. (Eastern time) on such specified trading day.
FAQ
What did ACMR disclose on this Form 4?
David H. Wang reported the vesting and acquisition of 545,400 stock options at an exercise price of $7.36 on October 27, 2025.
What triggered the 545,400 options to vest for ACMR’s CEO?
Vesting occurred when market capitalization reached $2,553,383,586, as defined in the grant’s calculation method.
When do these ACMR options expire?
The options expire on March 19, 2030.
What remains to vest under the 2020 performance grant?
Remaining shares vest upon the first trading day the market capitalization equals or exceeds $3,553,383,586.
What is the origin of the ACMR option grant?
The options stem from a March 20, 2020 performance grant tied to market capitalization milestones.